Eli Lilly (LLY) stock closed notably down on April 24 following reports that its newly launched oral obesity pill, Foundayo, is trailing Novo Nordisk’s (NVO) oral Wegovy in initial uptake. Moreover, the IQVIA prescription data for the week ending April 17 showed a modest 0.3% week-over-week decline in total prescriptions across Lilly's broader GLP-1 lineup. More News from Barchart Eli Lilly stock has been a major disappointment for investors in 2026, currently down more than 20% versus its year-to-dat ...